Tissue-type plasminogen activator (tPA) plays a major role in the fibrinolytic system. According to several reports, tPA may also have antiangiogenic properties, especially in combination with a free sulfhydryl donor (FSD). In the rat C6 glioma model, in vitro and in vivo tPA synthesis by glioma cells is enhanced by differentiation therapy. To address the antiangiogenic potential of tPA in this model, tPA was overexpressed in glioma tumors by ex vivo transduction of C6 cells with a lentiviral vector encoding tPA. The transduced cells were subcutaneously implanted into nude mice. Gene transfer allowed for efficient synthesis of tPA by the C6 tumors. Although the treatment of tPA þ tumor-bearing animals with the FSD captopril generated angiostatin in situ and reduced endothelial vascularization of the tumors, it had no effect on tumor growth. Alternative mechanisms could account for this lack of effect and consequently have important implications for vascular the treatment of glioblastoma.
Introduction
Tissue-type plasminogen activator (tPA), as expressed in vivo by endothelial cells, plays a major role in the fibrinolytic system. Proteolysis is involved in angiogenesis and tumor growth. However, the role of tPA in tumoral angiogenesis remains largely unknown despite reports of its potential antiangiogenic properties. Indeed, plasminogen activators can generate angiostatin from plasminogen in vivo. Angiostatin, which consists of the first four kringle domains of plasminogen (K1-4), 1 is one of a number of endogenous angiogenesis inhibitors generated by proteolytic cleavage of larger non-antiangiogenic precursor proteins. [2] [3] [4] [5] [6] [7] Gately et al. 2 have described the mechanism by which human prostate cancer cells convert plasminogen to angiostatin in vivo through the release of urokinase-type plasminogen activator (uPA) and free sulfhydryl donors (FSDs). They have also demonstrated the generation of angiostatin in vitro in a cell-free, fibrinfree system and described a two-step process by which plasminogen is first cleaved into plasmin by plasminogen activators (uPA, tPA or streptokinase). Secondly, in the presence of an FSD (N-acetylcysteine or captopril), they have shown that plasmin serves as both the substrate and the enzyme for the excision of the angiostatin fragment from plasmin itself or from plasminogen.
On the basis of these data, Merchan et al. 8 have treated patients with recombinant tPA (rtPA) and captopril. The antiangiogenic activity of their plasma on ex vivo endothelial-cell tube formation and endothelial cell proliferation was higher after treatment. This activity was largely retained after angiostatin was removed from plasma by immunoprecipitation, suggesting that the antiangiogenic activity generated by the rtPA and captopril treatment was somewhat independent of angiostatin. In vivo, angiogenesis in Matrigel plugs was substantially lower in mice treated with rtPA and captopril than in untreated mice. Soff et al. 9 conducted a phase I trial of administration of tPA in association with an FSD in patients with advanced solid tumors. Another group has administered rtPA and captopril to nude mice bearing human melanoma xenografts. They documented upregulation of angiostatin production in vivo and were able to report an inhibition of tumor growth. 10, 11 Finally, tPA or at least the recombinant association of its kringles 1 and 2 has been shown to be antiangiogenic. 12 Several observations have suggested that high tPA levels correlate with a better prognosis of various tumors, 13 whereas lower tPA activity correlates with both the recurrence and the hepatic metastasis of colorectal carcinomas.
14 Mice injected with colon cancer cells that overexpressed tPA had a markedly lower incidence of liver metastases and a higher survival rate than mice injected with untransfected colon cancer cells.
14 In summary, tPA may exhibit antiangiogenic properties both by itself and through the generation of other compounds.
Gliomas account for more than one-third of primary brain tumors. Among them, glioblastoma is the most common form. It is typically characterized by rapid cell proliferation and marked invasion of the surrounding tissues. Despite current modalities of treatment, the prognosis remains dismal. More than 90% of patients experience local recurrence, and the 5-year survival rate is only 9%. 15 Clearly, this demonstrates an unmet demand for therapeutic options. Glioblastoma is also highly angiogenic-a characteristic that correlates with clinical progression 16 and makes glioblastoma a good model for studying the therapeutic potential of angiogenesis inhibition in tumors.
We previously reported that differentiation therapy enhances tPA synthesis by rat C6 glioma cells. 17, 18 In this glioma model, we were interested in studying the antiangiogenic and/or antitumor potential of tPA in combination with an FSD. To evaluate this, we used a lentiviral vector to overexpress tPA in situ in C6 tumor cells, which were implanted into nude mice treated daily with the FSD, captopril. We then assessed the levels of angiostatin in situ, as well as the antiangiogenic and/or antitumor activity of this treatment.
Materials and methods

Cell culture
Rat C6 glioma cells 19 were grown at 37 1C with 5% CO 2 in Dulbecco's modified Eagle's medium (Invitrogen Corporation, Paisley, UK) supplemented with 10% fetal calf serum, 4 mM glutamin, 100 U ml À1 penicillin and 0.1 mg ml À1 streptomycin. Human umbilical vein endothelial cells were isolated by collagenase digestion, as previously described 20 and cultured at 37 1C with 5% CO 2 in EGM2-MV medium (Cambrex Bio Science, Walkersville, MD) that contained endothelial basal medium-2 supplemented with 5% fetal bovine serum, gentamicin, amphotericin B, hydrocortisone, ascorbic acid, vascular endothelial growth factor, basic fibroblast growth factor, human epidermal growth factor and insulin-like growth factor I.
Lentiviral vector production
Two lentiviral vectors were used: a green fluorescent protein (GFP)-encoding control vector named EW-ires-GFP and a GFP-and tPA-encoding vector named EWtPA-ires-GFP. Both directed expression of the transgenes from the elongation factor 1a promoter (EW) and contained an internal ribosomal entry site (ires).
tPA cDNA was amplified by PCR to introduce BamHI and XhoI restriction sites at the 5 0 and 3 0 ends, respectively. The PCR product was inserted into the pGEM Teasy plasmid (Promega, Madison, WI), verified by DNA sequencing, excised and subcloned into the BamHI and XhoI sites of the pLox-EW-ires-GFP plasmid (a gift from Dr P Salmon, University Medical Center, Geneva). pLox-EW-ires-GFP and pLox-EW-tPA-ires-GFP then served as gene transfer plasmids to produce the viral vectors.
Lentiviral vectors, pseudotyped with the vesicular stomatitis virus-G envelope protein, were produced by cotransfection of human embryonic kidney 293T cells with four plasmids, using the calcium-phosphate precipitation method. 21 pCMVR8.91 encodes the necessary human immunodeficiency virus structural genes. pMD.G bears the vesicular stomatitis virus-G envelope cDNA. Both plasmids were a gift from Dr D Trono (University of Geneva, www.tronolab.unige.ch). pAdVAntage (Promega) encodes VAI RNA, an inhibitor of the interferoninducible protein kinase (PKR). 22 Lastly, pLox-EWtPA-ires-GFP and pLox-EW-ires-GFP were the transfer plasmids carrying the gene of interest. Five million 293T cells were plated on the day prior to transfection in 10-cm round culture dishes containing 10 ml of Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum. The medium was changed 2 h before transfection. For each dish, 15 mg of pCMVR8.91, 5 mg of pMD.G, 10 mg of pAdVAntage and 20 mg of pLox-EW-gene plasmids were mixed. The DNA was diluted to a final volume of 250 ml with 2.5 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (pH 7.0) and supplemented with 250 ml of 0.5 M CaCl 2 . The DNA-CaCl 2 solution was added dropwise to 500 ml of 0.28 M NaCl, 0.05 M 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (pH 7.0) and 1.5 mM Na 2 HPO 4 under bubbling air. The mixture was incubated for 20 min at room temperature and then added dropwise to the 293T cells. After 16 h of incubation at 37 1C and 5% CO 2 , the medium was aspirated, 15 ml of fresh medium added and then incubated for a further 24 h. At the end of the second incubation, the supernatant was collected and passed through a 0.45-mm sterile filter. Lentivectors were concentrated Â 500 by three rounds of ultracentrifugation and stored at À80 1C.
Lentivector titers were determined by transduction of HeLa cells followed by flow cytometry analysis (FACSCalibur; Becton Dickinson, Franklin Lakes, NJ). A total of 5 Â 10 4 HeLa cells were plated in six-well plates in RPMI-10% fetal calf serum. Serial dilutions of lentivector preparations were added. The plates were centrifuged for 1 h at 2500 r.p.m. and incubated for 72 h in a regular CO 2 incubator. Cells were trypsinized, washed twice in phosphate-buffered saline-0.5% bovine serum albumin and fixed in 2% paraformaldehyde before flow cytometry analysis. Vector titer was calculated (10 5 Â % transduced cells/volume (ml)) using transduced cell populations for which the percentage of positive cells was lower than 15. Virus titers were expressed as transduction units per milliliter (TU ml
À1
).
In vitro transduction of C6 cells C6 cells (10 5 ) were plated in a 24-well plate for 24 h. Before transduction, the culture medium was replaced by 500 ml of fresh medium. The lentiviral vectors were added at a multiplicity of infection of 10, in the presence of polybrene (final concentration: 8 mg ml À1 ), and the plate was centrifuged for 1 h at 1200 g and then incubated for 16 h at 37 1C.
Transgene expression analysis
Expression of the GFP transgene was evaluated by flow cytometry. Supernatants and tumor extracts were assayed for tPA antigen by enzyme-linked immunosorbent assay (ELISA) (Imulyse; Biopool AB, Umea, Sweden), which reacts with both free tPA and tPA complexed with its inhibitor PAI-I.
SDS-polyacrylamide gel electrophoresis zymography SDS-polyacrylamide gel electrophoresis (SDS-PAGE) zymography was carried out on supernatants of C6 cultures as previously described. 23 After electrophoresis, 10% polyacrylamide gel was washed in 2.5% Triton X-100 for 1 h, followed by a wash in distilled water. Fibrinolytic activity was detected by placing the gel on a plasminogen fibrin agarose underlay that was incubated at 37 1C for 16 h. Molecular weight calibration was performed using known molecular weight standards run under the same conditions, together with standard rtPA (Actilyse; Boehringer Ingelheim, Reims, France) and uPA.
Angiostatin generation in vitro
Supernatants from non-transduced C6 cells, EW-ires-GFP-transduced cells and EW-tPA-ires-GFP-transduced cells were harvested after 24 h of culture of 20 Â 10 6 cells and concentrated 20-fold on centrifugal filter units Centricon (Millipore, Danvers, MA). Using doses based on in vitro work by Merchan et al., 8 2 mM human plasminogen (Chromogenix AB, Milano, Italy), 1 mM captopril (Sigma, Saint-Quentin Fallavier, France) and 100 ml of concentrated supernatant were diluted in a medium containing 50 mM Tris, pH 9, and 20 mM NaCl to achieve a final reaction volume of 250 ml. After incubation at 37 1C for 16 h, angiostatin generation was determined by western blot analysis.
In vivo experimental model
In vivo experimentation was carried out on 8-week-old male nude mice at the INSERM U318 animal care facility. On day 0, tumors were implanted subcutaneously in the right leg by injecting 5 Â 10 5 of non-transduced C6 cells or C6 cells that had been transduced by the EW-ires-
Five groups were formed, consisting of mice bearing non-transgenic tumors (group G0),
. Each day, treated animals (G3 and G4) were injected intraperitoneally with captopril (7.5 mg kg À1 ) diluted in 100 ml of 1 Â sterile phosphate-buffered saline. Tumors were measured with calipers on days 9, 11 and 14 to estimate their volume according to length (mm) Â the square of the width (mm 2 ) Â p/6. Tumors reached 2 cm length on day 14 when the animals were killed. Each tumor was then collected, measured as described and dissected into four parts. One portion was fixed in formol, embedded in paraffin and sectioned. A second portion was frozen in liquid azote using cryogel (Tissutek, Osaka, Japan) and stored at À80 1C before sectioning. The remaining portions were frozen at À20 1C before homogenization in a buffer composed of 75 mM acetic acid, 225 mM NaCl, 75 mM KCl, 10 mM EDTA, 100 mM arginin and 0.25% Triton X-100, pH 4.2. 24 Tissue extracts were then centrifuged for 10 min at 3000 g at 4 1C. Supernatants were collected and conserved at À80 1C before ELISA and western blot analysis were performed.
Histological analysis
Paraffin-embedded sections were stained with hematoxylin and eosin and later examined by light microscopy.
Anti-CD31 immunohistochemistry
Frozen sections were fixed in 4% paraformaldehyde and incubated overnight with a 1:2000 dilution of rat antimouse CD31 primary antibody (Pharmingen International, San Diego, CA). After neutralization with 10% goat serum, the biotined secondary antibody (goat antirat) was added at a 1:5000 dilution. Following incubation for 1 h at room temperature, a complex was formed between biotin and the streptavidin-peroxidase conjugate (Dako, Trappes, France). One hour later, the sections were stained with diaminobenzidine substrate-chromogen. The number of vessels (defined as a lumen lined entirely by marked endothelial cells) per sectional area of tumor was assessed by the HOME microscope work station. 25 Western blot analysis To assess in vitro and in vivo angiostatin generation, western blot analysis was performed on treated supernatants and tumor extracts. Treated supernatant (50 ml) or equal amounts of proteins from tissue samples, as determined by Biuret assay (Roche Diagnostics, Basel, Switzerland), were loaded and separated by SDS-PAGE on a 10% polyacrylamide gel. This was followed by protein transfer on a nitrocellulose membrane. The membrane was incubated overnight with a 1:100 dilution of rabbit polyclonal anti-human plasminogen primary antibody (Dako). After washing with Tween-20/Trisbuffered saline and adding a 1:5000 dilution of horseradish peroxidase-conjugated secondary antibody (ECL kit; Amersham, Uppsala, Sweden), incubation was continued for 1 h. Protein bands were then detected by chemiluminescence.
Results
Overexpression of tPA by lentivector-transduced C6 glioma cells in vitro After transduction of C6 glioma cells by the control vector EW-ires-GFP and by the tPA-encoding vector EW-tPA-ires-GFP, expression of the reporter gene GFP was assessed by flow cytometry. On average, 80% of the transduced cells expressed GFP over a period of more than 6 months (Figures 1a and b) , suggesting a high transduction efficiency.
Expression of the tPA transgene was quantified by ELISA. Only EW-tPA-ires-GFP-transduced cells secreted tPA. Levels of tPA production were stable, as indicated 6 transduced cells/24 h versus 2.1 ± 2.3 ng for non-transduced cells and 0.7 ± 0.6 ng for EW-ires-GFP-transduced cells (data not shown). Fibrinolytic activity of the secreted tPA was controlled by SDS-PAGE zymography after placing the electrophoresis gel on a plasminogen fibrin agarose underlay. Only EW-tPA-ires-GFP-transduced cells showed fibrinolytic activity (Figure 1c, lanes 4-6) .
Proliferation rates of transduced and non-transduced cells, which were the same in vitro (data not shown), enabled us to ensure that the presence of the transgenes did not impair cell viability.
Angiostatin generation in vitro
Incubation of supernatant from non-transduced cells or GFP þ cells with plasminogen and captopril resulted in moderate generation of plasmin but minor angiostatin formation ( Figure 2, lanes 2 and 3) . By contrast, with incubated supernatant from GFP þ tPA þ cells, plasminogen conversion to plasmin was markedly increased, and consequently much higher levels of angiostatin were produced ( Figure 2, lane 4) . We observed several angiostatin isoforms of approximately 50 and 48 kDa and were thus able to document angiostatin generation in vitro, through treatment of plasminogen with GFP þ tPA þ cell supernatant in combination with the FSD captopril.
Inhibition of in vivo angiogenesis by overexpression of tPA and treatment with captopril
We used ELISA to assay tPA antigen in tumor extracts ( Figure 3 ). As expected, tPA antigen was expressed only by GFP þ tPA þ -implanted tumors (groups G2 and G4). This finding confirmed efficient in situ tPA secretion by glioma tumors.
Western blot analysis of the tumor extracts confirmed the presence of angiostatin only in the GFP þ tPA þ -treated group (Figure 4) . From this, it appears that daily treatment with captopril resulted in the generation of angiostatin in C6 GFP þ tPA þ tumors. We then evaluated the effects of this treatment on tumor angiogenesis. Our examination of paraffinembedded tumor sections stained with hematoxylin and eosin revealed an apparent loss of vasculature in the GFP þ tPA þ -treated group G4 (Figure 5b ) as compared to the other groups (Figure 5a ). The tumor sections from group G4 showed areas that were poorly vascularized without necrosis (Figure 5b ). In addition, we saw that vascular thrombosis was more frequent in tumors that did not express tPA.
We then quantified the effect of tPA on tumor vascularization. Immunohistochemical staining for CD31 was performed to identify tumor-associated endothelial cells. In tumors from the GFP þ tPA þ -treated group (G4), small vessels and isolated endothelial cells were evident ( Figure 6A, panel b) , whereas in the other groups, larger vessels could be seen ( Figure 6A, panel c) . Evaluation of the CD31 þ vessels confirmed a significant reduction of endothelial vascularization in the GFP þ tPA þ -treated group (G4) when compared with the GFP þ tPA þ -untreated group (G2) and the control groups (G1 and G3) ( Figure 6B ).
Overexpression of tPA and treatment with captopril have no effect on tumor growth in vivo Although endothelial vascularization in GFP þ tPA þ tumors showed a significant decrease after treatment with captopril, no difference of the tumor volume was observed between the groups. The rate of tumor growth over a 14-day period, as well as the mean tumor volume at each time point, was similar ( Figure 7) . As a criterion to assess tumor growth, we verified the relevance of tumor volume by light microscopy on hematoxylin and eosinstained sections. No intratumoral cyst was observed, and the surface of necrosis was comparable among the different groups (data not shown). We concluded that despite their antiangiogenic activity, tPA and captopril had no effect in vivo on tumor mass in the C6 glioma model.
Discussion
Despite the current modalities of treatment, the prognosis of glioblastoma remains extremely poor. This emphasizes the need for optimizing therapy. As clinical progression of glioblastoma correlates with its vascularization, the inhibition of tumor angiogenesis, in combination with therapies that target tumor cells, has emerged as a promising therapeutic strategy. In the orthotopic rat C6 glioma model, the in vivo administration of retinoic acid induces cell differentiation and reduces tumor growth in a dose-dependant manner. Nevertheless, in test animals, mortality eventually occurs owing to massive intratumoral hemorrhages as a result of þ tPA þ cells were incubated with 2 mM human plasminogen (Chromogenix AB), 1 mM captopril (Sigma) and TrisNaCl medium for 16 h at 37 1C (final volume, 250 ml). As a positive control, 10 mg ml À1 recombinant tPA (Actilyse; Boehringer Ingelheim) was used instead of the supernatant. Angiostatin generation was evaluated by western blot analysis using a rabbit polyclonal antihuman plasminogen antibody and chemoluminescence detection. Figure 4 Angiostatin generation in vivo. Tissue extracts were prepared from frozen tumor fractions that had been homogenized in an acetate buffer and centrifuged. Angiostatin generation was evaluated by western blot analysis using rabbit polyclonal antihuman plasminogen antibody and chemoluminescence detection. C: positive control obtained after incubation of 2 mM human plasminogen with 10 mg ml À1 recombinant tPA and 1 mM captopril; G1: GFP þ -untreated tumor extract; G2: GFP þ tPA þ -untreated tumor extract; G3: GFP þ -treated tumor extract; G4: tumor extracts from GFP þ tPA þ -treated tumors implanted in five different mice. GFP, green fluorescent protein; tPA, tissue-type plasminogen activator.
Antiangiogenic properties of tPA F Solly et al increased tPA production by the treated tumors. 17, 18 Aside from its fibrinolytic activity, several reports suggest that tPA may also have antiangiogenic properties through and independently of angiostatin, especially when combined with FSDs. 2, 8, 10, 12 Although systematically administered angiostatin has shown limited efficacy in clinical trials, activity might be increased if angiostatin was produced inside the tumor and was, in addition, associated with other antiangiogenic compounds.
To assess the antiangiogenic and antitumoral potential of tPA in the rat C6 model, we overexpressed tPA in glioma tumors. This was done by the stable transduction of C6 cells with a lentiviral vector encoding tPA, which were then subcutaneously implanted into nude mice.
Gene transfer allowed for the efficient synthesis of tPA by glioma tumors (Figure 3) . In nude mice bearing tPA þ tumors, treatment with captopril generated angiostatin in situ (Figure 4 ), enabling us to show for the first time X 100 X 100 
Quantification of CD31 þ vessels by HOME microscope workstation on n non-necrotic sectional areas of tumor, and expression as mean number of vessels per mm 2 ± s.e. The sections studied were chosen at random and the whole smear was evaluated. G0: non-transgenic tumors; G1: GFP þ -untreated; G2: GFP þ tPA þ -untreated; G3: GFP þ -treated; G4: GFP þ tPA þ -treated. GFP, green fluorescent protein; tPA, tissue-type plasminogen activator.
Antiangiogenic properties of tPA F Solly et al that this treatment decreased intratumoral vascularization as assessed by immunostaining of endothelial cells ( Figure 6 ). However, in this preclinical study, tumor growth was not affected. This means that the combination of tPA with captopril had antiangiogenic effects through angiostatin and possibly through other generated antiangiogenic compounds but that it was not able to control tumor growth in the C6 glioma model. One explanation may be that C6 gliomas are very aggressive and show particular resistance to antiangiogenic treatment. 15 Furthermore, our findings are in accordance with numerous preclinical studies that reported the lack of angiostatin efficacy in the long term, despite a sustained delivery. In a murine model, the secretion of angiostatin by microencapsulated myoblasts was not sufficient to eliminate melanoma tumors in the long term. These tumors eventually became resistant to angiostatin treatment despite elimination of a majority of their endothelial cell content. 26 By contrast, our results contradict those of De Groot-Besseling et al. 10 These authors demonstrated an 83% inhibition of tumor growth by treatment with captopril and tPA and they also showed that captopril alone reduced tumor growth by up to 60%, an effect that we did not observe in the glioma model ( Figure 7) . However, the human melanoma xenograft model, as well as the doses and route of administration of tPA and captopril used in their work, is not comparable to ours.
A limitation to our study is that our model did not allow us to investigate a true dose-response relationship. Indeed, the dosage of captopril that we used was the optimal dose used by Merchan et al. 8 to obtain an antiangiogenic effect. We did not vary the dose of tPA either, as in our model, the generation of tPA was placed under the control of a non-modulated promoter. Furthermore, although we showed in vivo generation of angiostatin, we did not quantify the amount of angiostatin generated. So we could not determine whether or not the levels of angiostatin produced were enough to disrupt tumor vasculature to lead to tumor shrinkage, or only to reduce vasculature to a more normalized state allowing for better perfusion. However, other antiangiogenic compounds generated by the tPA and captopril treatment might be involved in our model, as previously suggested by Merchan et al. 8 In addition, tPA itself may have potential antiangiogenic properties. On the one hand, the recombinant association of its kringles 1 and 2 inhibits in vivo angiogenesis. 12 On the other hand, fibrinolytic activity of tPA might reduce tumor hypoxia. Hypoxia plays a major role in driving tumor growth by initiating angiogenesis and characterizes the transition from low-grade astrocytomas to aggressive glioblastomas. 27 On hematoxylin and eosin-stained sections, we saw that thrombosis was more prevalent in non-tPA-expressing tumors. This suggests that tPA might reduce tumor hypoxia and thereby contribute to the reduction of vascularization of tPA þ tumors. However, we were not able to observe any decrease in the number of blood vessels in the G2 group bearing tPA þ -untreated tumors in comparison with the G0 and G1 control groups ( Figure 6 ). This suggests that the effect of tPA alone was not sufficient to modify tumor vascularization in our model.
Finally, we showed that the levels of antiangiogenic compounds generated in situ induced a drastic antiangiogenic effect in our model (Figures 5 and 6 ). The absence of effect on tumor growth rather suggests possible mechanisms by which tumors might develop resistance to antiangiogenic therapy. Among these is the ability of cancer cells to form 'vasculogenic' channels, also called 'vasculogenic mimicry' in the literature. [28] [29] [30] [31] [32] [33] Although further studies would be needed to support this hypothesis, we previously described the in vitro potential of C6 cells to form vascular-like networks on Matrigel, which were resistant to angiostatin as well as to plasma treated with the combination of rtPA and captopril. ). Tumors were measured on day 9, day 11 and day 14 post-implantation. Their volume was calculated as follows: length2 (mm) Â square of the width (mm 2 ) Â p/6. Differences between the groups were nonsignificant. Black triangle and thick line: GFP þ -untreated (G1). Gray square and dotted line: GFP þ tPA þ -untreated (G2). Black circle and dotted line: GFP þ -treated (G3). Gray lozenge and thick line: GFP þ tPA þ -treated (G4). GFP, green fluorescent protein; tPA, tissue-type plasminogen activator.
